Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rawel SR Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

rawel sr

krka, d.d., novo mesto - indapamidas - pailginto atpalaidavimo tabletės - 1,5 mg - indapamide

Rawel SR Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

rawel sr

east europe pharmacy group, uab - indapamidas - pailginto atpalaidavimo tabletės - 1,5 mg - indapamide

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.

Nurofen Forte Strawberry Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

nurofen forte strawberry

lex ano, uab - ibuprofenas - geriamoji suspensija - 40 mg/ml - ibuprofen

Nurofen Forte Strawberry Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

nurofen forte strawberry

lex ano, uab - ibuprofenas - geriamoji suspensija - 40 mg/ml - ibuprofen

Capatox. Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

capatox.

uab daw lietuva, ukmergės g. 223-4, vilnius. - benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas - veikliosios medžiagos cas nr.: 68424-85-1, eb nr.: 270-325-2, veikliosios medžiagos pavadinimas: benzil-c12-c16-alkildimetilchloridas, alkil-c12-c16-dimetilbenzilamonio chloridas, koncentracija: 1.6% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui

Intra Hydrocare Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

intra hydrocare

intracare bv, voltaweg 4, 5466 az, veghel, nyderlandai - vandenilio peroksidas - veikliosios medžiagos cas nr.: 7722-84-1, eb nr.: 231-765-0, veikliosios medžiagos pavadinimas: vandenilio peroksidas, koncentracija: 59% , veiklioji - maisto ir pašarų sritis

Intra Multi-Des GA Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

intra multi-des ga

intracare bv, voltaweg 4, 5466 az, veghel, nyderlandai - glutaralis, glutaro aldehidas, 1,5-pentandialis; glutaralis, glutaro aldehidas, 1,5-pentandialis; glutaralis, glutaro aldehidas, 1,5-pentandialis - veikliosios medžiagos cas nr.: 111-30-8, eb nr.: 203-856-5, veikliosios medžiagos pavadinimas: glutaralis, glutaro aldehidas, 1,5-pentandialis, koncentracija: 12.5% , veiklioji; veikliosios medžiagos cas nr.: 111-30-8, eb nr.: 203-856-5, veikliosios medžiagos pavadinimas: glutaralis, glutaro aldehidas, 1,5-pentandialis, koncentracija: 12.5% , veiklioji; veikliosios medžiagos cas nr.: 111-30-8, eb nr.: 203-856-5, veikliosios medžiagos pavadinimas: glutaralis, glutaro aldehidas, 1,5-pentandialis, koncentracija: 12.5% , veiklioji - maisto ir pašarų sritis